NexImmune, Inc. (NEXI) Research
As a clinical-stage biotechnology firm, NexImmune, Inc. is dedicated to developing potentially curative treatments for individuals battling cancer and severe immune disorders. Their approach leverages T cell immunotherapies, based on their exclusive Artificial Immune Modulation (AIM) nanoparticle technology platform. The company's pipeline includes NEXI-001, an allogeneic cell therapy currently undergoing Phase I/II clinical trials for acute myeloid leukemia; NEXI-002, an autologous cell therapy also in Phase I/II studies, targeting relapsed or refractory multiple myeloma; and NEXI-003, an early-stage candidate designed to combat HPV-associated malignancies. NexImmune, Inc. was established in 2011 and is based in Gaithersburg, Maryland.
Market snapshot
- Symbol
- NEXI
- Price
- $0.00
- Day change
- 0.00%
- Market cap
- $139.0
- P/E ratio
- -0.00x
- 52-week range
- 0.0001-1.01
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $3.33
Recent news
- Italian state investor CDP to raise stake in payments group Nexi
Italian state investor CDP Equity plans to raise its stake in payments group Nexi to as much as 29.9%, it said on Monday, bolstering a player in a sector viewed as increasingly strategic.
- Italy's CDP against selling stake in Nexi, sources say
Italy's state lender Cassa Depositi e Prestiti (CDP) has no plans to divest from payments group Nexi NEXII.Mi, two sources familiar with the matter said on Wednesday.
Peer companies
Recent insider activity
- Jones Kristi — P-Purchase (1 shares) on 2024-06-11
- Marchio Albert N II — trade (0 shares) on 2024-04-05
- Roemer Alan S. — S-Sale (3833 shares) on 2023-11-21
- Roemer Alan S. — S-Sale (3992 shares) on 2023-11-22
- STOVER TIMOTHY — trade (0 shares) on 2023-08-30
Open NexImmune, Inc. (NEXI) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.